These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8043498)

  • 21. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
    Arnold JT; Liu X; Allen JD; Le H; McFann KK; Blackman MR
    Prostate; 2007 Aug; 67(11):1152-62. PubMed ID: 17503469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
    Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
    Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens.
    Avancès C; Georget V; Térouanne B; Orio F; Cussenot O; Mottet N; Costa P; Sultan C
    Mol Cell Endocrinol; 2001 Nov; 184(1-2):13-24. PubMed ID: 11694337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
    Attardi BJ; Burgenson J; Hild SA; Reel JR
    Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones.
    Schuurmans AL; Bolt J; Veldscholte J; Mulder E
    J Steroid Biochem Mol Biol; 1991; 40(1-3):193-7. PubMed ID: 1958520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells.
    Rahman MM; Miyamoto H; Takatera H; Yeh S; Altuwaijri S; Chang C
    J Biol Chem; 2003 May; 278(22):19619-26. PubMed ID: 12649293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
    Culig Z; Hobisch A; Cronauer MV; Cato AC; Hittmair A; Radmayr C; Eberle J; Bartsch G; Klocker H
    Mol Endocrinol; 1993 Dec; 7(12):1541-50. PubMed ID: 8145761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
    Nesslinger NJ; Shi XB; deVere White RW
    Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of steroid derivatives that function as potent antiandrogens.
    Miyamoto H; Marwah P; Marwah A; Yang Z; Chung CY; Altuwaijri S; Chang C; Lardy H
    Int J Cancer; 2005 Dec; 117(5):866-72. PubMed ID: 15981214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects.
    Térouanne B; Tahiri B; Georget V; Belon C; Poujol N; Avances C; Orio F; Balaguer P; Sultan C
    Mol Cell Endocrinol; 2000 Feb; 160(1-2):39-49. PubMed ID: 10715537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid androgen actions on calcium signaling in rat sertoli cells and two human prostatic cell lines: similar biphasic responses between 1 picomolar and 100 nanomolar concentrations.
    Lyng FM; Jones GR; Rommerts FF
    Biol Reprod; 2000 Sep; 63(3):736-47. PubMed ID: 10952915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
    Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M
    Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
    Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
    Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen independence of primary epithelial cultures of the prostate is associated with a down-regulation of androgen receptor gene expression.
    Grant ES; Batchelor KW; Habib FK
    Prostate; 1996 Dec; 29(6):339-49. PubMed ID: 8977630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
    Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
    Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
    Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor.
    Song LN; Coghlan M; Gelmann EP
    Mol Endocrinol; 2004 Jan; 18(1):70-85. PubMed ID: 14593076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
    Zhao XY; Peehl DM; Navone NM; Feldman D
    Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.